文献速递垂体与肾上腺疾病

糖皮质激素给药时间节律调控免疫细胞时钟基因:DREAM试验辅助研究

Circadian Rhythm of Glucocorticoid Administration Entrains Clock Genes in Immune Cells: A DREAM Trial Ancillary Study.
PubMed 文献 · J Clin Endocrinol Metab · 2018-01-01

65例患者和18例对照同意基因表达分析,结果显示患者基线时68个基因中19个表达异常,换药12周后其中18个恢复至对照水平。

要点

  • 肾上腺功能不全患者常规糖皮质激素治疗下外周血单核细胞时钟基因表达失调。
  • 每日一次改良释放氢化可的松治疗12周后,19个失调基因中18个恢复至健康对照水平。
  • WEE1、PRF1和PER3表达变化与糖化血红蛋白、炎症单核细胞及CD16+自然杀伤细胞相关。

核心结论

  • 标准治疗的肾上腺功能不全患者外周血单核细胞存在时钟基因失调,每日一次改良释放氢化可的松可使外周组织基因表达恢复至接近对照水平。

主要发现

  • 与健康对照相比,肾上腺功能不全患者基线时68个基因中19个被调节,其中18个在换药12周后恢复至对照水平。
  • 恢复至对照水平的基因包括ARNTL[BMAL](P=0.024)、CLOCK(P=0.016)、AANAT(P=0.021)、CREB1(P=0.010)、CREB3(P=0.037)、MAT2A(P=0.013)。
  • PRKAR1A、PRKAR2A和PRKCB均P<0.010;PER3、TIMELESS、CAMK2D、MAPK1、SP1、WEE1、CSNK1A1、ONP3和PRF1均P<0.001。
  • WEE1、PRF1和PER3表达变化与糖化血红蛋白、炎症单核细胞和CD16+自然杀伤细胞相关。

临床怎么用

  • 每日一次改良释放氢化可的松可使肾上腺功能不全患者外周血单核细胞时钟基因表达恢复至接近健康对照水平,与DREAM试验临床结局平行。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Adrenal insufficiency (AI) requires lifelong glucocorticoid (GC) replacement. Conventional therapies do not mimic the endogenous cortisol circadian rhythm. Clock genes are essential components of the machinery controlling circadian functions and are influenced by GCs. However, clock gene expression has never been investigated in patients with AI. OBJECTIVE: To evaluate the effect of the timing of GC administration on circadian gene expression in peripheral blood mononuclear cells (PBMCs) of patients from the Dual Release Hydrocortisone vs Conventional Glucocorticoid Replacement in Hypocortisolism (DREAM) trial. DESIGN: Outcome assessor-blinded, randomized, active comparator clinical trial. PARTICIPANTS AND INTERVENTION: Eighty-nine patients with AI were randomly assigned to continue their multiple daily GC doses or switch to an equivalent dose of once-daily modified-release hydrocortisone and were compared with 25 healthy controls; 65 patients with AI and 18 controls consented to gene expression analysis. RESULTS: Compared with healthy controls, 19 of the 68 genes were found modulated in patients with AI at baseline, 18 of which were restored to control levels 12 weeks after therapy was switched: ARNTL [BMAL] (P = 0.024), CLOCK (P = 0.016), AANAT (P = 0.021), CREB1 (P = 0.010), CREB3 (P = 0.037), MAT2A (P = 0.013); PRKAR1A, PRKAR2A, and PRKCB (all P < 0.010) and PER3, TIMELESS, CAMK2D, MAPK1, SP1, WEE1, CSNK1A1, ONP3, and PRF1 (all P < 0.001). Changes in WEE1, PRF1, and PER3 expression correlated with glycated hemoglobin, inflammatory monocytes, and CD16+ natural killer cells. CONCLUSIONS: Patients with AI on standard therapy exhibit a dysregulation of circadian genes in PBMCs. The once-daily administration reconditions peripheral tissue gene expression to levels close to controls, paralleling the clinical outcomes of the DREAM trial (NCT02277587).

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Venneri MA, Hasenmajer V, Fiore D, et al. Circadian Rhythm of Glucocorticoid Administration Entrains Clock Genes in Immune Cells: A DREAM Trial Ancillary Study. J Clin Endocrinol Metab. 2018. PMID: 29846607. doi:10.1210/jc.2018-00346

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。